RE:CAR-T Abstract from Mayo Clinic (Vile group) using pelaTwo major take-aways:
1) "These dual-specific (DS) CAR T expressed a memory phenotype and persisted for much longer than conventional CAR T cells".
[Conventional CAR-T cells typically experience T cell exhaustion with loss of T-cell persistence and loss of effectiveness resulting from the immunosuppressive TME which ONCY's pelareorep is able to overcome by remodelling the TME for the addition of various I/O agents like CAR-T therapy, immune checkpoint inhibitors, bispecifics, ADCs, and small molecules like PARP and CDK 4/6 inhibitors]
2) " We will go on to develop a clinical trial in which CAR T cells will be pre-loaded with OV and administered intravenously to patients with HGG, followed by systemic boosting with virus to re-activate DS CAR T cells against their tumor".
[ Boosting with pelareorep has demonstrated "curative" effects ]